Definitely would help, as part of a most probably already complicated therapeutic regime :)

No, it still wouldn’t address the insulin resistance, just the consequences of the β-cell dysfunction. Ideally therapy would address the hyperglycaemia and preserve β-cell functionality. Currently insulin is prescribed in T2D when two oral agents aren’t effective at controlling hyperglycaemia. So while potentially applicable, it would not be a solution.

Because type two doesn’t have issues with insulin production, but insulin sensitivity. So the pancreas produces, but the body isn’t responding as it should.